Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: GLP 4716; GLPG-4716; OAT-889; OATD 01

Latest Information Update: 28 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Molecure
  • Class Amines; Antiasthmatics; Antifibrotics; Chlorobenzenes; Hepatoprotectants; Morpholines; Nonsteroidal anti-inflammatories; Piperidines; Small molecules; Triazoles
  • Mechanism of Action Acidic mammalian chitinase inhibitors; Chitotriosidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis; Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary sarcoidosis
  • Phase I Interstitial lung diseases
  • Research Fibrosis; Non-alcoholic steatohepatitis
  • No development reported Asthma; Chronic obstructive pulmonary disease
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 21 May 2024 Molecure receives national regulatory approval from Denmark, France, Greece, Germany, and Norway for its phase II KITE trial for pulmonary sarcoidosis
  • 22 Mar 2024 Molecure plans to file an IND application with the EMA and Norwegian Medical Products Agency in European Union and Norway for Pulmonary sarcoidosis
  • 04 Mar 2024 Phase-II clinical trials in Pulmonary sarcoidosis in United Kingdom, USA (PO) in March 2024 (NCT06205121)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top